Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068094 · ClinicalTrials.gov registry record · Phase 1
The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics
A Phase 1 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00068094: Clinical Trial Phase 1 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
NCT00068094 is a Phase 1 study that was terminated before completion, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00068094, a Phase 1 study, was terminated before completion, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether probiotics, bacteria that may improve liver health, can effectively treat a chronic condition in diabetics that increases fat in the liver.
Interventions
- DRUG Probiotic-containing powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-02 |
| Phase | Phase 1 |
Why NCT00068094 stopped before completion
NCT00068094 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 1 intervention - of which Probiotic-containing powder is the first listed.
NCT00068094 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00068094 about?
NCT00068094 is a clinical study titled "The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics". The purpose of this study is to determine whether probiotics, bacteria that may improve liver health, can effectively treat a chronic condition in diabetics that increases fat in the liver.
What is the current status of trial NCT00068094?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2005-07. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00068094?
The interventions under investigation include: Probiotic-containing powder (DRUG).
Who is sponsoring clinical trial NCT00068094?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00068094's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia